Rege Nephro

Rege Nephro is a Japanese biotechnology company developing cell therapies to treat chronic kidney disease using nephron progenitor cells differentiated from induced pluripotent stem (iPS) cells. It is developing nephron progenitor cell-based regenerative products intended to restore nephron function and reduce or eliminate patients' dependence on dialysis. The company targets the large chronic kidney disease patient population in Japan and internationally, aiming to offer a curative alternative to lifelong dialysis through advanced regenerative medicine.